For the quarter ending 2025-09-30, AURA had -$59,800K decrease in cash & cash equivalents over the period. -$20,189K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -26,130 | -54,502 |
| Depreciation expense | 280 | 577 |
| Accretion income on marketable securities | 337 | 785 |
| Stock-based compensation expense | 3,688 | 7,347 |
| Other non-cash items | 0 | 27 |
| Non-cash lease expense | 392 | 757 |
| Prepaid expenses and other assets | 1,534 | -2,882 |
| Other long-term assets | 92 | -333 |
| Accounts payable | 602 | -1,018 |
| Accrued expenses and other liabilities | 3,345 | 910 |
| Operating lease liabilities | -358 | -657 |
| Net cash used in operating activities | -20,144 | -44,129 |
| Purchases of property and equipment | 45 | 226 |
| Purchases of marketable securities | 73,974 | 9,984 |
| Proceeds from sale of marketable securities | - | 0 |
| Maturities of marketable securities | 30,000 | 60,000 |
| Net cash provided by investing activities | -44,019 | 49,790 |
| Proceeds from exercise of stock options | 1,008 | 2 |
| Proceeds from issuance of common stock from follow-on offering, net of issuance costs | 0 | 46,517 |
| Proceeds from issuance of pre-funded warrants from follow-on offering, net of issuance costs | 0 | 14,156 |
| Proceeds from issuance of common stock warrants from follow-on offering, net of issuance costs | 0 | 9,254 |
| Proceeds from issuance of common stock under atm facility, net of issuance costs | 3,287 | - |
| Proceeds from espp purchases | 68 | 96 |
| Net cash provided by financing activities | 4,363 | 70,025 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -59,800 | 75,686 |
| Effect of exchange rate changes on cash | -26 | - |
| Cash and cash equivalents at beginning of period | 32,461 | - |
| Cash and cash equivalents at end of period | 48,321 | - |
Aura Biosciences, Inc. (AURA)
Aura Biosciences, Inc. (AURA)